Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Phase 2b, Multicenter Study to Evaluate the Safety, Efficacy, and Tolerability of SNA-120 (Pegcantratinib) Ointment in Subjects With Pruritus Associated With Psoriasis Vulgaris
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Jun 2019
Price :
$35
*
At a glance
- Drugs Pegcantratinib (Primary)
- Indications Plaque psoriasis; Pruritus
- Focus Therapeutic Use
- Sponsors Sienna Biopharmaceuticals
- 10 Jun 2019 Results presented in a Sienna Biopharmaceuticals Media Release.
- 10 Jun 2019 According to a Sienna Biopharmaceuticals media release, data will be presented at the World Congress of Dermatology 2019.
- 03 Dec 2018 According to a Sienna Biopharmaceuticals media release, subjects treated with SNA-120 (0.05%) achieved statistical significance, compared to vehicle, on important pre-specified regulatory endpoints of psoriasis disease severity.